Overexpression Of Eg5 Predicts Unfavorable Prognosis In Non-Muscle Invasive Bladder Urothelial Carcinoma

Sentai Ding,Naidong Xing,Jiaju Lu,Hui Zhang,Koji Nishizawa,Shuai Liu,Xiaodong Yuan,Yejun Qin,Ying Liu,Osuma Ogawa,Hiroyuki Nishiyama
DOI: https://doi.org/10.1111/j.1442-2042.2011.02751.x
2011-01-01
International Journal of Urology
Abstract:Objective:To investigate the relationship between Eg5 expression and prognosis of patients with non-muscle invasive bladder urothelial carcinoma.Methods:Eg5 expression was examined by immunohistochemistry in non-muscle invasive urothelial carcinoma specimens (grade: G1, 32 cases; G2, 92 cases; and G3, 39 cases. Stage: pTa, 49 cases and pT1, 114 cases). The correlation between clinicopathological characteristics and Eg5 expression was evaluated. The prognostic significance of Eg5 immunoreactivity was analyzed through survival analysis in 163 non-muscle invasive cases that were treated with transurethral resection and adjuvant intravesical instillations.Results:The expression of Eg5 was significantly associated with tumor grade (P = 0.006), with a trend towards significant association with stage (P = 0.057). The 163 patients with non-muscle invasive tumors were regularly followed with the mean of 32.52 (from 6 to 72) months. Univariate analysis showed Eg5 overexpression exhibited a significant unfavorable influence on intravesical recurrence (P = 0.012) while having only a marginal correlation with disease progression (P = 0.070). Subsequent Cox hazard multivariate analysis showed that both grade (P = 0.045) and Eg5 expression (P = 0.029) were independent predictors for early intravesical recurrence.Conclusions:Overexpression of Eg5 correlates with poor differentiation of bladder cancer, and it represents an independent prognostic factor in predicting early intravesical recurrence in non-muscle invasive bladder carcinoma patients.
What problem does this paper attempt to address?